Skip to content
POM-V Prescription Required Companion Animal

Canigen Parvo-C Lyophilisate for Suspension for Injection for Dogs

Active ingredient: Canine parvovirus

Form

Injection

Species

Dogs

Manufacturer

Intervet International B.V.

VMD MA No.

06376/4108

What it's used for

For active immunisation of dogs to prevent mortality, clinical signs and viral excretion following canine parvovirus infection. Onset of immunity: 1 week....

Full indications, dosage and side effects ↓
View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Canine parvovirus

  1. 1

    Ask your vet for a written prescription

    They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.

  2. 2

    Fill it at a registered online retailer

    The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Canigen Parvo-C Lyophilisate for Suspension for Injection for Dogs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 18 Mar 2026.

For active immunisation of dogs to prevent mortality, clinical signs and viral excretion
following canine parvovirus infection.
Onset of immunity: 1 week.
Duration of immunity: 3 years.
Reconstitute the vaccine with 1 ml solvent or 1 ml (1 dose) of the inactivated vaccines
listed in section 4.8.
Subcutaneous use.
Avoid contamination of vaccine with traces of chemical sterilising agents. Do not use
chemicals such as disinfectant or spirit to disinfect the skin prior to inoculation.
Maternal antibodies can negatively interfere with the efficacy of a vaccine. Strict
adherence to the vaccination programme is therefore recommended.
Vaccination programme:
Primary vaccination course:
A single injection should establish active immunity to disease caused by canine
parvovirus infection in dogs of 10 weeks of age or older. Where earlier protection is
required a first dose may be given to puppies from 4 weeks of age, but because
maternally derived passive antibody can interfere with the response to vaccination a final
dose at 10 weeks of age or older is generally recommended.
Booster vaccination:
It is recommended that dogs be revaccinated against canine parvovirus every 3 years.
None.
A diffuse swelling, up to 5 mm in diameter, may commonly be observed at the site of
injection. Occasionally this swelling may be hard and painful and last for up to 3 days
post injection.
A transient acute hypersensitivity reaction – with signs that may include lethargy, facial
oedema, pruritus, vomiting or diarrhoea – may occur shortly after vaccination in very rare
cases. Such reaction may evolve to a more severe condition (anaphylaxis), which may
be life-threatening with additional signs like dyspnoea and collapse. If such reactions
occur, appropriate treatment is recommended.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals, including isolated reports).

Revised: December 2024
AN: 01537/2024
Special precautions for use in animals:
Animals that have received a corresponding anti-serum or immunosuppressive drugs
should not be vaccinated until an interval of at least 4 weeks has elapsed.
Vaccinated dogs may excrete the parvovirus vaccine strain at very low levels for up to 8
days after vaccination. However, there is no evidence of any reversion to virulence of the
vaccine strain and therefore no need to separate unvaccinated dogs from contact
with recently vaccinated dogs.
Special precautions to be taken by the person administering the medicinal product to
animals:
In the case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
Safety and efficacy data are available which demonstrate that this vaccine can be mixed
and administered with the inactivated vaccines in the Canigen range for subcutaneous
administration against canine leptospirosis caused by all or some of the following
serovars: L. interrogans serogroup Canicola serovar Canicola, L. serogroup
Icterohaemorrhagiae serovar Copenhageni, L. interrogans serogroup Australis serovar
Bratislava, and L. kirschneri serogroup Grippotyphosa serovar Bananal/Liangguang.
After administration with one of the leptospirosis vaccines, a mild and transient increase
in body temperature (≤ 1 °C) may occur for a few days after vaccination, with some pups
showing less activity and/or a reduced appetite. A small transient swelling 4 cm), which
can occasionally be firm and painful on palpation, may be observed at the site of
injection. Any such swelling will either have disappeared or be clearly diminished by
14 days post-vaccination.
After mixed administration of an overdose of Canigen Parvo-C and an overdose of the
leptospirosis vaccines in the Canigen range, transient local reactions such as diffuse to
firm swellings from 1 to 5 cm in diameter may be observed, usually these will persist no
longer than 5 weeks, however some may take a little longer to completely disappear.
Safety and efficacy data are available which demonstrate that this vaccine can be mixed
and administered with the inactivated vaccine in the Canigen range against rabies. After
administration with the rabies vaccine, where this product is authorised, transient local
reactions such as diffuse to firm swellings from 1 to 4 cm in diameter may be observed
for up to 3 weeks after vaccination. The swellings may be painful for up to 3 days post
dosing.
Safety and efficacy data are available which demonstrate that this vaccine can be
administered at the same time but not mixed with the inactivated vaccine in the Canigen
range against Bordetella bronchiseptica.
Product information of the relevant Canigen vaccines should be consulted before mixed
product administration.

No information is available on the safety and efficacy of this vaccine when used with any
other veterinary medicinal product except the products mentioned above. A decision to
use this vaccine before or after any other veterinary medicinal product therefore needs to
be made on a case by case basis.

Revised: December 2024
AN: 01537/2024
Store in a refrigerator (2 C – 8 C).
Do not freeze.
Protect from light.
Care should be taken to avoid prolonged or repetitive exposure to high ambient
temperatures following withdrawal from the refrigerator prior to use - in hot summer
conditions vaccine potency can be severely reduced within a few hours.
Not applicable.
5. IMMUNOLOGICAL PROPERTIES
Pharmacotherapeutic group: Immunologicals for ; live viral vaccines for dogs
ATCvet code: QI07AD01
The vaccine contains attenuated antigens to stimulate active immunity against canine
parvovirus disease.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.

Medication costs adding up?

Pet insurance can cover prescription medications. Find the right policy for your pet.

Compare insurance

Find cheaper vets near you

Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.